US20040127502A1 - Use of GAL3 antagonist for treatment of depression - Google Patents
Use of GAL3 antagonist for treatment of depression Download PDFInfo
- Publication number
- US20040127502A1 US20040127502A1 US10/723,961 US72396103A US2004127502A1 US 20040127502 A1 US20040127502 A1 US 20040127502A1 US 72396103 A US72396103 A US 72396103A US 2004127502 A1 US2004127502 A1 US 2004127502A1
- Authority
- US
- United States
- Prior art keywords
- branched
- straight chained
- alkyl
- aryl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 101150103804 GAL3 gene Proteins 0.000 title claims abstract description 23
- 102100039558 Galectin-3 Human genes 0.000 title claims abstract description 23
- 239000005557 antagonist Substances 0.000 title abstract description 9
- 238000011282 treatment Methods 0.000 title description 17
- 208000020401 Depressive disease Diseases 0.000 title description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 370
- 238000000034 method Methods 0.000 claims abstract description 208
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 83
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 81
- 230000036506 anxiety Effects 0.000 claims abstract description 79
- 229940044551 receptor antagonist Drugs 0.000 claims abstract description 42
- 239000002464 receptor antagonist Substances 0.000 claims abstract description 42
- 239000003937 drug carrier Substances 0.000 claims abstract description 41
- 239000000203 mixture Substances 0.000 claims abstract description 7
- 230000008569 process Effects 0.000 claims abstract description 4
- 125000003118 aryl group Chemical group 0.000 claims description 1031
- 125000001072 heteroaryl group Chemical group 0.000 claims description 660
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims description 644
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 440
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 436
- 125000003342 alkenyl group Chemical group 0.000 claims description 427
- 125000000304 alkynyl group Chemical group 0.000 claims description 427
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 400
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 336
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 225
- 125000004432 carbon atom Chemical group C* 0.000 claims description 176
- -1 methylenedioxy group Chemical group 0.000 claims description 148
- 229910052799 carbon Inorganic materials 0.000 claims description 118
- 229910052717 sulfur Inorganic materials 0.000 claims description 97
- 150000003839 salts Chemical class 0.000 claims description 95
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 87
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 87
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 82
- 102000005962 receptors Human genes 0.000 claims description 68
- 108020003175 receptors Proteins 0.000 claims description 68
- 230000027455 binding Effects 0.000 claims description 67
- 229910052731 fluorine Inorganic materials 0.000 claims description 67
- 229910052801 chlorine Inorganic materials 0.000 claims description 64
- 229910052739 hydrogen Inorganic materials 0.000 claims description 63
- 229910003844 NSO2 Inorganic materials 0.000 claims description 59
- 125000000217 alkyl group Chemical group 0.000 claims description 56
- 229910052740 iodine Inorganic materials 0.000 claims description 52
- 229910052757 nitrogen Inorganic materials 0.000 claims description 49
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 49
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 claims description 48
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 claims description 48
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 48
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 48
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 43
- 229910052760 oxygen Inorganic materials 0.000 claims description 38
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 35
- 241000282414 Homo sapiens Species 0.000 claims description 35
- 150000004292 cyclic ethers Chemical class 0.000 claims description 35
- 150000004294 cyclic thioethers Chemical class 0.000 claims description 35
- 101000608757 Homo sapiens Galectin-3 Proteins 0.000 claims description 34
- 102000048551 human LGALS3 Human genes 0.000 claims description 34
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 32
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 28
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 24
- 125000005485 noradamantyl group Chemical group 0.000 claims description 24
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 16
- 150000002466 imines Chemical class 0.000 claims description 16
- 150000001336 alkenes Chemical class 0.000 claims description 14
- 101001042451 Homo sapiens Galectin-1 Proteins 0.000 claims description 13
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 10
- 102000010909 Monoamine Oxidase Human genes 0.000 claims description 8
- 108010062431 Monoamine oxidase Proteins 0.000 claims description 8
- 229910052794 bromium Inorganic materials 0.000 claims description 8
- 229960003638 dopamine Drugs 0.000 claims description 5
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 4
- 108010078791 Carrier Proteins Proteins 0.000 claims description 4
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 claims description 4
- 102000008092 Norepinephrine Plasma Membrane Transport Proteins Human genes 0.000 claims description 4
- 108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 claims description 4
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 claims description 4
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 claims description 4
- 108060003345 Adrenergic Receptor Proteins 0.000 claims 12
- 102000017910 Adrenergic receptor Human genes 0.000 claims 12
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 4
- 102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 claims 2
- 101001042446 Homo sapiens Galectin-2 Proteins 0.000 claims 2
- 229960001340 histamine Drugs 0.000 claims 2
- 101100388144 Xenopus laevis drd5 gene Proteins 0.000 claims 1
- 150000005624 indolones Chemical class 0.000 abstract description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 185
- 125000001246 bromo group Chemical group Br* 0.000 description 184
- 239000000460 chlorine Substances 0.000 description 43
- 241000700159 Rattus Species 0.000 description 29
- 238000012360 testing method Methods 0.000 description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 14
- 238000012048 forced swim test Methods 0.000 description 14
- 125000001624 naphthyl group Chemical group 0.000 description 14
- 239000001301 oxygen Substances 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 239000011593 sulfur Substances 0.000 description 14
- 125000000335 thiazolyl group Chemical group 0.000 description 14
- 230000003997 social interaction Effects 0.000 description 12
- 239000000935 antidepressant agent Substances 0.000 description 11
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 11
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 11
- 229940005513 antidepressants Drugs 0.000 description 9
- 230000037120 immobility Effects 0.000 description 9
- 230000006399 behavior Effects 0.000 description 8
- 150000001204 N-oxides Chemical class 0.000 description 7
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 7
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 7
- 125000005605 benzo group Chemical group 0.000 description 7
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 7
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 7
- 125000002541 furyl group Chemical group 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- 125000002883 imidazolyl group Chemical group 0.000 description 7
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 7
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 7
- 125000001041 indolyl group Chemical group 0.000 description 7
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 7
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 7
- 125000001786 isothiazolyl group Chemical group 0.000 description 7
- 125000000842 isoxazolyl group Chemical group 0.000 description 7
- 125000001715 oxadiazolyl group Chemical group 0.000 description 7
- 125000002971 oxazolyl group Chemical group 0.000 description 7
- 125000005545 phthalimidyl group Chemical group 0.000 description 7
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 7
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 7
- 125000003373 pyrazinyl group Chemical group 0.000 description 7
- 125000003226 pyrazolyl group Chemical group 0.000 description 7
- 125000002098 pyridazinyl group Chemical group 0.000 description 7
- 125000004076 pyridyl group Chemical group 0.000 description 7
- 125000000714 pyrimidinyl group Chemical group 0.000 description 7
- 125000000168 pyrrolyl group Chemical group 0.000 description 7
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 7
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 7
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 7
- 230000009182 swimming Effects 0.000 description 7
- 125000001113 thiadiazolyl group Chemical group 0.000 description 7
- 125000001544 thienyl group Chemical group 0.000 description 7
- 125000004306 triazinyl group Chemical group 0.000 description 7
- 125000001425 triazolyl group Chemical group 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000009194 climbing Effects 0.000 description 6
- 229960002464 fluoxetine Drugs 0.000 description 6
- 230000036651 mood Effects 0.000 description 5
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 4
- 208000011688 Generalised anxiety disease Diseases 0.000 description 4
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 230000001430 anti-depressive effect Effects 0.000 description 4
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 4
- SHOMMGQAMRXRRK-UHFFFAOYSA-N bicyclo[3.1.1]heptane Chemical compound C1C2CC1CCC2 SHOMMGQAMRXRRK-UHFFFAOYSA-N 0.000 description 4
- 208000029364 generalized anxiety disease Diseases 0.000 description 4
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 4
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 4
- 229960002748 norepinephrine Drugs 0.000 description 4
- 208000019906 panic disease Diseases 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 3
- JRICMQCTFYLWOU-UHFFFAOYSA-N N1C(=CC2=CC=CC=C12)N.C1(O)=C(O)C(=CC=C1)N Chemical compound N1C(=CC2=CC=CC=C12)N.C1(O)=C(O)C(=CC=C1)N JRICMQCTFYLWOU-UHFFFAOYSA-N 0.000 description 3
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 3
- 101000608761 Rattus norvegicus Galectin-3 Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 3
- 229960004782 chlordiazepoxide Drugs 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 208000024714 major depressive disease Diseases 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 229960002296 paroxetine Drugs 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 102220101620 rs759365577 Human genes 0.000 description 3
- 102220059023 rs786201869 Human genes 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000020925 Bipolar disease Diseases 0.000 description 2
- 206010012239 Delusion Diseases 0.000 description 2
- 206010054089 Depressive symptom Diseases 0.000 description 2
- 101000887490 Homo sapiens Guanine nucleotide-binding protein G(z) subunit alpha Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
- 102100033928 Sodium-dependent dopamine transporter Human genes 0.000 description 2
- 206010042458 Suicidal ideation Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000000338 anxiogenic effect Effects 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- 230000009193 crawling Effects 0.000 description 2
- 231100000868 delusion Toxicity 0.000 description 2
- 230000009189 diving Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 208000024732 dysthymic disease Diseases 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 102000052301 human GNAZ Human genes 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 229940001470 psychoactive drug Drugs 0.000 description 2
- 239000004089 psychotropic agent Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 2
- 229960002073 sertraline Drugs 0.000 description 2
- 230000007958 sleep Effects 0.000 description 2
- 125000006529 (C3-C6) alkyl group Chemical group 0.000 description 1
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical class C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 1
- TXQAZWIBPGKHOX-UHFFFAOYSA-N 1H-indol-3-amine Chemical compound C1=CC=C2C(N)=CNC2=C1 TXQAZWIBPGKHOX-UHFFFAOYSA-N 0.000 description 1
- MGBKJKDRMRAZKC-UHFFFAOYSA-N 3-aminobenzene-1,2-diol Chemical group NC1=CC=CC(O)=C1O MGBKJKDRMRAZKC-UHFFFAOYSA-N 0.000 description 1
- 210000002348 5-ht neuron Anatomy 0.000 description 1
- 208000007415 Anhedonia Diseases 0.000 description 1
- 206010002652 Anorgasmia Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010011971 Decreased interest Diseases 0.000 description 1
- 102000004300 GABA-A Receptors Human genes 0.000 description 1
- 108090000839 GABA-A Receptors Proteins 0.000 description 1
- 102000019432 Galanin Human genes 0.000 description 1
- 101800002068 Galanin Proteins 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 241001282135 Poromitra oscitans Species 0.000 description 1
- 101100335469 Rattus norvegicus Fst gene Proteins 0.000 description 1
- 206010043169 Tearfulness Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 206010048232 Yawning Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000003555 analeptic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 208000025307 bipolar depression Diseases 0.000 description 1
- 230000008309 brain mechanism Effects 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000003370 grooming effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960001078 lithium Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 description 1
- 230000001730 monoaminergic effect Effects 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229940053544 other antidepressants in atc Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- Depression is the most common of mental disorders and yet is often underdiagnosed and undertreated, inflicting substantial morbidity and psychosocial impairment on its sufferers. Depression is mainly characterized by sadness, flatness, loss of feeling, anhedonia (lack of pleasure), tearfulness, agitation or retardation, thoughts of guilt, and worthlessness; in severe cases, suicide, hallucinations and delusions.
- Depression can be mainly categorized into bipolar disorders, identifying wide swings of mood; major depressive illness, marked by severe depressive symptoms but without manic swings; and less defined milder forms of bipolar and major depression that fall short of the specific diagnostic criteria e.g. dysthymic disorder (formerly called depressive neurosis).
- the symptomatology and diagnostic criteria for depression are set out in the DSMIV guidelines (American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders). Although many patients have single episodes of major depressive illness, the condition also can be repetitive, and this recurrent condition is frequently called unipolar depressive illness.
- depressive illness a markedly gloomy mood in which there is a loss of interest in life, and general feelings of hopelessness and worthlessness.
- Depressive symptoms range in severity from mild mood swings to severe delusions about self-worth, accomplishments, and the future.
- the key clinical features of anxiety disorders relate to various combinations of psychological and physical manifestations of anxiety, not attributable to real danger and occurring either in attacks (panic disorder PD) or as a persisting state (generalized anxiety disorder -GAD).
- Other neurotic features may be present (obsessional or hysterical symptoms) but do not dominate the clinical picture.
- TCAs tricylic antidepressants
- SSRIs selective serotonin re-uptake inhibitors
- MAOIs monoamine oxidase inhibitors
- This theory postulates that a certain level of amines and/or receptor sensitivity to catecholamines functions to generate a normal mood.
- a receptor insensitivity, a depletion of monoamines, or a decrease in their release, synthesis or storage have been postulated to lead to depression.
- a variety of pharmacological agents have been employed to treat depression based on the catecholamine-indolamine hypothesis of depression.
- Drugs used to treat depression include MAOIs, atypical antipsychotics, lithium, TCAs, and SSRIs.
- off-label agents such as antiepileptics are used to treat depression in treatment-resistant patients.
- Tricyclic antidepressants are about equal to SSRIs in effectiveness against depression thus providing supporting evidence for the catecholamine-indolamine hypothesis of depression.
- SSRIs have largely displaced TCAs because of side effects associated with TCAs and the need to monitor EKG and plasma drug concentration.
- Adverse effects on sexual function primarily anorgasmia and delayed ejaculation, have been consistently reported.
- Other, common side-effects include sleep disorders, yawning, weight changes, suicidal ideation and extrapyramidal-like side-effects such as dystonic reactions.
- OCD obsessive compulsive disorder
- GAD generalized anxiety disorder
- PD panic disorder
- GAL3 receptor may play a role in controlling the activity of catecholamine and indolamine neurons in the CNS.
- Galanin is known to hyperpolarize neurons, including monoaminergic neurons (Seutin, et al., 1989) and to have inhibitory effects on 5-HT neurons (Xu, et al., 1998), and dopamine neurons (Gopalan, et al., 1993; De Weille, et al., 1989; Jansson, et al., 1989; Nordstrom, et al., 1987; Weiss, et al., 1998).
- the rat Forced Swim Test is a behavioral test that is used to screen compounds for antidepressant efficacy (Porsolt et al., 1977, 1978; Porsolt, 1981). This test is widely used as it is reliable across laboratories, relatively easy to perform and is sensitive to the effects of some of the major classes of antidepressant drugs, including TCAs and MAOIs, and various atypical antidepressants. Furthermore, this test is relatively selective for antidepressant drugs, as few psychoactive drugs produce similar behavioral actions in the FST.
- SIT Social Interaction Test
- rats previously housed singly are placed in a familiar, dimly lit, test arena with weight-matched, novel partners.
- the principal anxiogenic stimulus under these conditions is the partner novelty, which involves an unconditioned response to a potential threat.
- the following behaviors are scored as active social interaction: grooming, sniffing, biting, boxing, wrestling, following, crawling over and crawling under.
- the synthesis of novel pyrimidines which bind selectively to the cloned human GAL3 receptor, compared to other cloned human G-protein coupled receptors, as measured in in vitro assays is disclosed.
- the synthesis of indolones which bind selectively to the cloned human GAL3 receptor, compared to other cloned human G-protein coupled receptors, as measured in in vitro assays is disclosed.
- the in vitro receptor assays described hereinafter were performed using various cultured cell lines, each transfected with and expressing only a single galanin-type receptor.
- the present invention provides a method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat the subject's depression wherein the compound has the structure:
- W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R 11 is H, straight chained or branched C 1 -C 7 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , aryl, or aryl (C 1 -C 6 )alkyl;
- R 12 is straight chained or branched C 1 -C 7 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , or —(CH 2 ) m —Z;
- R 13 is a bicyclic alkyl ring system, adamantyl, noradamantyl, C 3 -C 10 cycloalkyl, heteroaryl, aryl, aryl(C 1 -C 6 )alkyl, Q 1 or Q 2 ;
- aryl may be substituted with one or more C 1 -C 10 straight chained or branched alkyl, aryl, heteroaryl, or N(R 19 )—Z;
- each J is independently O, S, C(R 22 ) 2 or NR 4 ;
- R 4 is H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl or aryl;
- R 14 is H, straight chained or branched C 1 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m —Z;
- R 15 is straight chained or branched C 3 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, (C(R 19 ) 2 ) m N(R 16 ) 2 or (C(R 19 ) 2 ) m —Z;
- R 16 is straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 17 is independently H; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , —COOR 21 , straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) n —O—(CH 2 ) m —CH 3 ;
- R 18 is straight chained or branched C 1 -C 6 alkyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 19 is independently H, or straight chained or branched C 1 -C 6 alkyl
- each R 20 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , or —COOR 21 ; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 21 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl, or aryl(C 1 -C 6 ) alkyl;
- each R 22 is independently H, F, Cl or C 1 -C 4 straight chained or branched alkyl
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- U is O, —NR 16 , S, C(R 17 ) 2 , or —NSO 2 R 16 ;
- Z is C 3 -C 10 cycloalkyl, C 4 -C 7 cyclic ether, C 4 -C 7 cyclic thioether, aryl, or heteroaryl; or
- the present invention provides a method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat the subject's depression wherein the compound has the structure:
- W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R 11 is H, straight chained or branched C 1 -C 7 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , aryl or aryl(C 1 -C 6 )alkyl;
- R 12 is straight chained or branched C 1 -C 7 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , or —(CH 2 ) m —Z;
- R 13 is a bicyclic alkyl ring system, aryl or aryl (C 1 -C 6 ) alkyl;
- R 14 is H, straight chained or branched C 1 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m —Z;
- R 15 is straight chained or branched C 3 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m —Z;
- U is O, —NR 16 , S, C(R 17 ) 2 , or —NSO 2 R 16 ;
- Z is C 3 -C 10 cycloalkyl, aryl, or heteroaryl
- R 16 is straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 17 is independently H; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , —COOR 21 , straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) n —O—(CH 2 ) m —CH 3 ;
- R 18 is straight chained or branched C 1 -C 6 alkyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 19 is independently H, or straight chained or branched C 1 -C 6 alkyl
- each R 20 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , or —COOR 21 ; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 21 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl(C 1 -C 6 ) alkyl;
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- the present invention provides a method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat the subject's depression wherein the compound has the structure:
- W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R 13 is an aryl, adamantyl, noradamantyl, C 3 -C 10 cycloalkyl, heteroaryl, Q 1 or Q 2 ;
- aryl may be substituted with one or more C 1 -C 10 straight chained or branched alkyl, aryl, heteroaryl, or N(R 19 )—Z;
- each J is independently O, S, C(R 22 ) 2 or NR 4 ;
- R 4 is —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl or aryl;
- R 14 is H, straight chained or branched C 1 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m —Z;
- R 15 is straight chained or branched C 3 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m —Z;
- U is O, —NR 16 , S, C(R 17 ) 2 , or —NSO 2 R 16 ;
- Z is C 3 -C 10 cycloalkyl, aryl, or heteroaryl
- R 16 is straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 17 is independently H; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , —COOR 21 , straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) n —O—(CH 2 ) m —CH 3 ;
- R 18 is straight chained or branched C 1 -C 6 alkyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 19 is independently H, or straight chained or branched C 1 -C 6 alkyl
- each R 20 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , or —COOR 21 ; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 21 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl(C 1 -C 6 ) alkyl;
- each R 22 is independently H, F, Cl or C 1 -C 4 straight chained or branched alkyl
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- the present invention provides a method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat the subject's depression wherein the compound has the structure:
- W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R 13 is a bicyclic alkyl ring system, aryl or aryl (C 1 -C 6 )alkyl;
- R 14 is H, straight chained or branched C 1 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m —Z;
- R 15 is (C(R 19 ) 2 ) m —N(R 16 ) 2 ;
- Z is C 3 -C 10 cycloalkyl, aryl, or heteroaryl
- R 16 is straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 17 is independently H; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , —COOR 21 , straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) n —O—(CH 2 ) m —CH 3 ;
- each R 19 is independently H, or straight chained or branched C 1 -C 6 alkyl
- each R 21 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl(C 1 -C 6 )alkyl;
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- the present invention also provides a method of treating a subject suffering from anxiety which comprises administering to the subject an amount of compound effective to treat the subject's anxiety wherein the compound has the structure:
- W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R 11 is H, straight chained or branched C 1 -C 7 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , aryl, or aryl (C 1 -C 6 )alkyl;
- R 12 is straight chained or branched C 1 -C 7 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , or —(CH 2 ) m —Z;
- R 13 is a bicyclic alkyl ring system, adamantyl, noradamantyl, C 3 -C 10 cycloalkyl, heteroaryl, aryl, aryl(C 1 -C 6 )alkyl, Q 1 or Q 2 ;
- aryl may be substituted with one or more C 1 -C 10 straight chained or branched alkyl, aryl, heteroaryl, or N(R 19 )—Z;
- each J is independently O, S, C(R 22 ) 2 or NR 4 ;
- R 4 is H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl or aryl;
- R 14 is H, straight chained or branched C 1 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m —Z;
- R 15 is straight chained or branched C 3 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, (C(R 19 ) 2 ) m N(R 16 ) 2 or (C(R 19 ) 2 ) m —Z
- R 16 is straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 17 is independently H; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , —COOR 21 , straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) n —O—(CH 2 ) m —CH 3 ;
- R 18 is straight chained or branched C 1 -C 6 alkyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 19 is independently H, or straight chained or branched C 1 -C 6 alkyl
- each R 20 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , or —COOR 21 ; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 21 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl, or aryl(C 1 -C 6 )alkyl;
- each R 22 is independently H, F, Cl or C 1 -C 4 straight chained or branched alkyl
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- U is O, —NR 16 , S, C(R 17 ) 2 , or —NSO 2 R 16 ;
- Z is C 3 -C 10 cycloalkyl, C 4 -C 7 cyclic ether, C 4 -C 7 cyclic thioether, aryl, or heteroaryl; or
- the invention provides a method of treating a subject suffering from anxiety which comprises administering to the subject an amount of compound effective to treat the subject's anxiety wherein the compound has the structure:
- W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R 11 is H, straight chained or branched C 1 -C 7 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , aryl or aryl(C 1 -C 6 ) alkyl;
- R 12 is straight chained or branched C 1 -C 7 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , or —(CH 2 ) m —Z;
- R 13 is a bicyclic alkyl ring system, aryl or aryl(C 1 -C 6 )alkyl;
- R 14 is H, straight chained or branched C 1 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m —Z;
- R 15 is straight chained or branched C 3 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m —Z;
- U is O, —NR 16 , S, C(R 17 ) 2 , or —NSO 2 R 16 ;
- Z is C 3 -C 10 cycloalkyl, aryl, or heteroaryl
- R 16 is straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 17 is independently H; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , —COOR 21 , straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) n —O—(CH 2 ) m —CH 3 ;
- R 18 is straight chained or branched C 1 -C 6 alkyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 19 is independently H, or straight chained or branched C 1 -C 6 alkyl
- each R 20 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , or —COOR 21 ; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 21 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl(C 1 -C 6 )alkyl;
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- the invention provides a method of treating a subject suffering from anxiety which comprises administering to the subject an amount of compound effective to treat the subject's anxiety wherein the compound has the structure:
- W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R 13 is an aryl, adamantyl, noradamantyl, C 3 -C 10 cycloalkyl, heteroaryl, Q 1 or Q 2 ;
- aryl may be substituted with one or more C 1 -C 10 straight chained or branched alkyl, aryl, heteroaryl, or N(R 19 )—Z;
- each J is independently O, S, C(R 22 ) 2 or NR 4 ;
- R 4 is —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl or aryl;
- R 14 is H, straight chained or branched C 1 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m —Z;
- R 15 is straight chained or branched C 3 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m —Z;
- U is O, —NR 16 , S, C(R 17 ) 2 , or —NSO 2 R 16 ;
- Z is C 3 -C 10 cycloalkyl, aryl, or heteroaryl
- R 16 is straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 17 is independently H; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , —COOR 21 , straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) n —O—(CH 2 ) m —CH 3 ;
- R 18 is straight chained or branched C 1 -C 6 alkyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 19 is independently H, or straight chained or branched C 1 -C 6 alkyl
- each R 20 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , or —COOR 21 ; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 21 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl(C 1 -C 6 )alkyl;
- each R 22 is independently H, F, Cl or C 1 -C 4 straight chained or branched alkyl
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- the invention provides a method of treating a subject suffering from anxiety which comprises administering to the subject an amount of compound effective to treat the subject's anxiety wherein the compound has the structure:
- W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R 13 is a bicyclic alkyl ring system, aryl or aryl(C 1 -C 6 )alkyl;
- R 14 is H, straight chained or branched C 1 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m —Z;
- R 15 is (C(R 19 ) 2 ) m —N(R 16 ) 2 ;
- Z is C 3 -C 10 cycloalkyl, aryl, or heteroaryl
- R 16 is straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 17 is independently H; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , —COOR 21 , straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) n —O—(CH 2 ) m —CH 3 ;
- each R 19 is independently H, or straight chained or branched C 1 -C 6 alkyl
- each R 21 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl(C 1 -C 6 )alkyl;
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- the invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the structure:
- W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R 11 is H, straight chained or branched C 1 -C 7 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , aryl, or aryl (C 1 -C 6 )alkyl;
- R 12 is straight chained or branched C 1 -C 7 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , or —(CH 2 ) m —Z;
- R 13 is a bicyclic alkyl ring system, adamantyl, noradamantyl, C 3 -C 10 cycloalkyl, heteroaryl, aryl, aryl(C 1 -C 6 )alkyl, Q 1 or Q 2 ;
- aryl may be substituted with one or more C 1 -C 10 straight chained or branched alkyl, aryl, heteroaryl, or N(R 19 )—Z;
- each J is independently O, S, C(R 22 ) 2 or, NR 4 ;
- R 4 is H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl or aryl;
- R 14 is H, straight chained or branched C 1 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m —Z;
- R 15 is straight chained or branched C 3 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, (C(R 19 ) 2 ) m N(R 16 ) 2 or (C(R 19 ) 2 ) m —Z;
- R 16 is straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 17 is independently H; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , —COOR 21 , straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) n —O—(CH 2 ) m —CH 3 ;
- R 18 is straight chained or branched C 1 -C 6 alkyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 19 is independently H, or straight chained or branched C 1 -C 6 alkyl
- each R 20 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR21, —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , or —COOR 21 ; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 21 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl, or aryl(C 1 -C 6 ) alkyl;
- each R 22 is independently H, F, Cl or C 1 -C 4 straight chained or branched alkyl
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- U is O, —NR 16 , S, C(R 17 ) 2 , or —NSO 2 R 16 ;
- Z is C 3 -C 10 cycloalkyl, C 4 -C 7 cyclic ether, C 4 -C 7 cyclic thioether, aryl, or heteroaryl; or
- the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the structure:
- W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R 11 is H, straight chained or branched C 1 -C 7 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , aryl or aryl(C 1 -C 6 )alkyl;
- R 12 is straight chained or branched C 1 -C 7 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , or —(CH 2 ) m —Z;
- R 13 is a bicyclic alkyl ring system, aryl or aryl (C 1 -C 6 ) alkyl;
- R 14 is straight chained or branched C 1 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m —Z;
- U is O, —NR 16 , S, C(R 17 ) 2 , or —NSO 2 R 16 ;
- Z is C 3 -C 10 cycloalkyl, aryl, or heteroaryl
- R 16 is straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 17 is independently H; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , —COOR 21 , straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) n —O—(CH 2 ) m —CH 3 ;
- R 18 is straight chained or branched C 1 -C 6 alkyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 19 is independently H, or straight chained or branched C 1 -C 6 alkyl
- each R 20 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , or —COOR 21 ; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 21 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl(C 1 -C 6 ) alkyl;
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the structure:
- W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R 13 is an aryl, adamantyl, noradamantyl, C 3 -C 10 cycloalkyl, heteroaryl, Q 1 or Q 2 ;
- aryl may be substituted with one or more C 1 -C 10 straight chained or branched alkyl, aryl, heteroaryl, or N(R 19 )—Z;
- each J is independently O, S, C(R 22 ) 2 or NR 4 ;
- R 4 is —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl or aryl;
- R 14 is H, straight chained or branched C 1 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m —Z;
- R 15 is straight chained or branched C 3 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m —Z;
- U is O, —NR 16 , S, C(R 17 ) 2 , or —NSO 2 R 16 ;
- Z is C 3 -C 10 cycloalkyl, aryl, or heteroaryl
- R 16 is straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 17 is independently H; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , —COOR 21 , straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) n —O—(CH 2 ) m —CH 3 ;
- R 18 is straight chained or branched C 1 -C 6 alkyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 19 is independently H, or straight chained or branched C 1 -C 6 alkyl
- each R 20 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , or —COOR 21 ; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 21 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl(C 1 -C 6 ) alkyl;
- each R 22 is independently H, F, Cl or C 1 -C 4 straight chained or branched alkyl
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the structure:
- W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R 13 is a bicyclic alkyl ring system, aryl or aryl (C 1 -C 6 ) alkyl;
- R 14 is H, straight chained or branched C 1 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m —Z;
- R 15 is (C(R 19 ) 2 ) m —N(R 16 ) 2 ;
- Z is C 3 -C 10 cycloalkyl, aryl, or heteroaryl
- R 16 is straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, (CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 17 is independently H; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , —COOR 21 , straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) n —O—(CH 2 ) m —CH 3 ;
- each R 19 is independently H, or straight chained or branched C 1 -C 6 alkyl
- each R 21 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl(C 1 -C 6 ) alkyl;
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- the invention provides a compound having the structure:
- W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R 11 is H, straight chained or branched C 1 -C 7 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , aryl, or aryl (C 1 -C 6 )alkyl;
- R 12 is straight chained or branched C 1 -C 7 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , or —(CH 2 ) m —Z;
- R 13 is a bicyclic alkyl ring system, adamantyl, noradamantyl, C 3 -C 10 cycloalkyl, heteroaryl, aryl, aryl(C 1 -C 6 )alkyl, Q 1 or Q 2 ;
- aryl may be substituted with one or more C 1 -C 10 straight chained or branched alkyl, aryl, heteroaryl, or N(R 19 )—Z;
- each J is independently O, S, C(R 22 ) 2 or NR 4 ;
- R 4 is H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl or aryl;
- R 14 is H, straight chained or branched C 1 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m —Z;
- R 15 is straight chained or branched C 3 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, (C(R 19 ) 2 ) m N(R 16 ) 2 or (C(R 19 ) 2 ) m —Z;
- R 16 is straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 17 is independently H; —OR 21 , —OCOR 21 —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , —COOR 21 , straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) n —O—(CH 2 ) m —CH 3 ;
- R 18 is straight chained or branched C 1 -C 6 alkyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 19 is independently H, or straight chained or branched C 1 -C 6 alkyl
- each R 20 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , or —COOR 21 ; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 21 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl, or aryl(C 1 -C 6 ) alkyl;
- each R 22 is independently H, F, Cl or C 1 -C 4 straight chained or branched alkyl
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- U is O, —NR 16 , S, C(R 17 ) 2 , or —NSO 2 R 16 ;
- Z is C 3 -C 10 cycloalkyl, C 4 -C 7 cyclic ether, C 4 -C 7 cyclic thioether, aryl, or heteroaryl; or
- the invention provides a compound having the structure:
- W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R 11 is H, straight chained or branched C 1 -C 7 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , aryl or aryl (C 1 -C 6 ) alkyl;
- R 12 is straight chained or branched C 1 -C 7 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , or —(CH 2 ) m —Z;
- R 13 is a bicyclic alkyl ring system, aryl or aryl (C 1 -C 6 ) alkyl;
- R 14 is H, straight chained or branched C 1 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m —Z;
- R 15 is straight chained or branched C 3 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m —Z;
- U is O, —NR 16 , S, C(R 17 ) 2 , or —NSO 2 R 16 ;
- Z is C 3 -C 10 cycloalkyl, aryl, or heteroaryl
- R 16 is straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 17 is independently H; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , —COOR 21 , straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) n —O—(CH 2 ) m —CH 3 ;
- R 18 is straight chained or branched C 1 -C 6 alkyl, (CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 19 is independently H, or straight chained or branched C 1 -C 6 alkyl
- each R 20 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , or —COOR 21 ; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 21 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl(C 1 -C 6 ) alkyl;
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- the invention provides a compound having the structure:
- W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R 13 is an aryl, adamantyl, noradamantyl, C 3 -C 10 cycloalkyl, heteroaryl, Q 1 or Q 2 ;
- aryl may be substituted with one or more C 1 -C 10 straight chained or branched alkyl, aryl, heteroaryl, or N(R 19 )—Z;
- each J is independently O, S, C(R 22 ) 2 or NR 4 ;
- R 4 is —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl or aryl;
- R 14 is H, straight chained or branched C 1 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m —Z;
- R 15 is straight chained or branched C 3 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m —Z;
- U is O, —NR 16 , S, C(R 17 ) 2 , or —NSO 2 R 16 ;
- Z is C 3 -C 10 cycloalkyl, aryl, or heteroaryl
- R 16 is straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 17 is independently H; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , —COOR 21 , straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) n —O—(CH 2 ) m —CH 3 ;
- R 18 is straight chained or branched C 1 -C 6 alkyl, (CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 19 is independently H, or straight chained or branched C 1 -C 6 alkyl
- each R 20 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , or —COOR 21 ; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 21 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl(C 1 -C 6 )alkyl;
- each R 22 is independently H, F, Cl or C 1 -C 4 straight chained or branched alkyl
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- the invention provides a compound having the structure:
- W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R 13 is a bicyclic alkyl ring system, aryl or aryl (C 1 -C 6 ) alkyl;
- R 14 is H, straight chained or branched C 1 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m —Z;
- R 15 is (C(R 19 ) 2 ) m —N(R 16 ) 2 ;
- Z is C 3 -C 10 cycloalkyl, aryl, or heteroaryl
- R 16 is straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained ox branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 17 is independently H; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , —COOR 21 , straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) n —O—(CH 2 ) m —CH 3 ;
- each R 19 is independently H, or straight chained or branched C 1 -C 6 alkyl
- each R 21 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl(C 1 -C 6 ) alkyl;
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- the invention also provides a method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat, the subject's depression wherein the compound has the structure:
- each of Y 1 , Y 2 , Y 3 , and Y 4 is independently H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 4 , —SR 4 , —OCOR 4 , —COR 4 , —NCOR 4 , —N(R 4 ) 2 , —CON(R 4 ) 2 , or —COOR 4 ; aryl or heteroaryl; or any two of Y 1 , Y 2 , Y 3 and Y 4 present on adjacent carbon atoms can constitute
- each R 4 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl (C 1 -C 6 ) alkyl;
- A is A′, Q 3 , Q 4 , Q 5 , straight chained or branched C 1 -C 7 alkyl, aryl, heteroaryl, aryl(C 1 -C 6 ) alkyl, heteroaryl (C 1 -C 6 ) alkyl, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl; or (CHR 17 )—(CHR 17 ) n —Z;
- R 1 and R 2 are each independently H, straight chained or branched C 1 -C 7 alkyl, —F, —Cl, —Br, —I, —NO 2 , or —CN;
- R 3 is H, straight chained or branched C 1 -C 7 alkyl, —F, —Cl, —Br, —I, —NO 2 , —CN, —OR 6 , aryl or heteroaryl;
- R 5 is straight chained or branched C 1 -C 7 alkyl, —N(R 4 ) 2 , —OR 6 or aryl;
- R 6 is straight chained or branched C 1 -C 7 alkyl or aryl
- each R 17 is independently H; straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) n —O—(CH 2 ) m —CH 3 ;
- each R 20 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , or —COOR 21 ; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 21 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl(C 1 -C 6 )alkyl;
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- each p is an integer from 0 to 2 inclusive;
- U is O, —NR 16 , S, C(R 17 ) 2 , or —NSO 2 R 16 ;
- Z is C 3 -C 10 cycloalkyl, C 4 -C 7 cyclic ether, C 4 -C 7 cyclic thioether, aryl, or heteroaryl;
- R 16 is straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- B is aryl, heteroaryl, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, tricyclic heteroaryl or Q 6 ; provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following —F, —Cl, —Br, —I, —CN, methyl, ethyl or methoxy;
- a tricyclic heteroaryl is a fused three member aromatic system in which one or more of the rings is heteroaryl; carbazole; or acridine;
- each R 22 is independently H, F,
- the invention provides a method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat the subject's depression wherein the compound has the structure:
- each of Y 1 , Y 2 , Y 3 , and Y 4 is independently H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 4 , —SR 4 , —OCOR 4 , —COR 4 , —NCOR 4 , N(R 4 ) 2 , —CON(R 4 ) 2 , or —COOR 4 ; aryl or heteroaryl; or any two of Y 1 , Y 2 , Y 3 and Y 4 present on adjacent carbon atoms can constitute a
- each R 4 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl(C 1 -C 6 )alkyl;
- A is A′, straight chained or branched C 1 -C 7 alkyl, aryl, heteroaryl, aryl(C 1 -C 6 )alkyl or heteroaryl (C 1 -C 6 )alkyl;
- R 1 and R 2 are each independently H, straight chained or branched C 1 -C 7 alkyl, —F, —Cl, —Br, —I, NO 2 , or —CN;
- R 3 is H, straight chained or branched C 1 -C 7 alkyl, —F, —Cl, —Br, —I, —NO 2 , —CN, —OR 6 aryl or heteroaryl;
- R 5 is straight chained or branched C 1 -C 7 alkyl, —N(R 4 ) 2 , —OR 6 or aryl;
- R 6 is straight chained or branched C 1 -C 7 alkyl or aryl
- B is aryl, or heteroaryl; provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following —F, —Cl, —Br, —I, —CN, methyl, ethyl or methoxy;
- n is an integer from 1 to 4 inclusive
- the invention provides a method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat the subject's depression wherein the compound has the structure:
- each of Y 1 , Y 2 , Y 3 , and Y 4 is independently H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN ; —OR 4 , —SR 4 , —OCOR 4 , —COR 4 , —NCOR 4 , —N(R 4 ) 2 , —CON(R 4 ) 2 , or —COOR 4 ; aryl or heteroaryl; or any two of Y 1 , Y 2 , Y 3 and Y 4 present on adjacent carbon atoms can constitute
- each R 4 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl (C 1 -C 6 ) alkyl;
- A is A′, straight chained or branched C 1 -C 7 alkyl, aryl, heteroaryl, aryl(C 1 -C 6 )alkyl or heteroaryl (C 1 -C 6 ) alkyl;
- B is aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, tricyclic heteroaryl or Q 6 ;
- a tricyclic heteroaryl is a fused three ring aromatic system in which one or more of the rings is heteroaryl; carbazole; or acridine;
- n is an integer from 1 to 4 inclusive
- each R 22 is independently H, F, Cl, or straight chained or branched C 1 -C 4 alkyl
- the invention provides a method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat the subject's depression wherein the compound has the structure:
- each of Y 1 , Y 2 , Y 3 , and Y 4 is independently H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 4 , —SR 4 , —OCOR 4 , —COR 4 , —NCOR 4 , —N(R 4 ) 2 , —CON(R 4 ) 2 , or —COOR 4 ; aryl or heteroaryl; or any two of Y 1 , Y 2 , Y 3 and Y 4 present on adjacent carbon atoms can constitute
- each R 4 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl(C 1 -C 6 )alkyl;
- A is Q 3 , Q 4 , Q 5 , aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, or (CHR 17 )—(CHR 17 ) n —Z;
- each R 17 is independently H; straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) n —O—(CH 2 ) m —CH 3 ;
- each R 20 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or C 5 -C 7 cycloalkenyl;.
- each R 21 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl or aryl;
- each R 22 is independently H, F, Cl, or straight chained or branched C 1 -C 4 alkyl
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- each p is an integer from 0 to 2 inclusive;
- U is O, —NR 16 , S, C(R 17 ) 2 , or —NSO 2 R 16 ;
- Z is C 3 -C 10 cycloalkyl, C 4 -C 7 cyclic ether, C 4 -C 7 cyclic thioether, aryl, or heteroaryl;
- R 16 is straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- B is aryl, or heteroaryl; provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following —F, —Cl, —Br, —I, —CN, methyl, ethyl or methoxy;
- the invention provides a method of treating a subject suffering from anxiety which comprises administering to the subject an amount of compound effective to treat the subject's anxiety wherein the compound has the structure:
- each of Y 1 , Y 2 , Y 3 , and Y 4 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 4 , —SR 4 , —OCOR 4 , —COR 4 , —NCOR 4 , —N(R 4 ) 2 , —CON(R 4 ) 2 , or —COOR 4 ; aryl or heteroaryl; or any two of Y 1 , Y 2 , Y 3 and Y 4 present on adjacent carbon atoms can
- each R 4 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl(C 1 -C 6 )alkyl;
- A is A′, Q 3 , Q 4 , Q 5 , straight chained or branched C 1 -C 7 alkyl, aryl, heteroaryl, aryl(C 1 -C 6 )alkyl, heteroaryl(C 1 -C 6 )alkyl, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl; or (CHR 17 )—(CHR 17 ) n —Z;
- R 1 and R 2 are each independently H, straight chained or branched C 1 -C 7 alkyl, —F, —Cl, —Br, —I, —NO 2 , or —CN;
- R 3 is H, straight chained or branched C 1 -C 7 alkyl, —F, —Cl, —Br, —I, —NO 2 , —CN, —OR 6 , aryl or heteroaryl;
- R 5 is straight chained or branched C 1 -C 7 alkyl, —N(R 4 ) 2 , —OR 6 or aryl;
- R 6 is straight chained or branched C 1 -C 7 alkyl or aryl
- each R 17 is independently H; straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) n —O—(CH 2 ) m —CH 3 ;
- each R 20 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , or —COOR 21 ; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 21 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl(C 1 -C 6 )alkyl;
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- each p is an integer from 0 to 2 inclusive;
- U is O, —NR 16 , S, C(R 17 ) 2 , or —NSO 2 R 16 ;
- Z is C 3 -C 10 cycloalkyl, C 4 -C 7 cyclic ether, C 4 -C 7 cyclic thioether, aryl, or heteroaryl;
- R 16 is straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- B is aryl, heteroaryl, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, tricyclic heteroaryl or Q 6 ; provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following —F, —Cl, —Br, —I, —CN, methyl, ethyl or methoxy;
- a tricyclic heteroaryl is a fused three member aromatic system in which one or more of the rings is heteroaryl; carbazole; or acridine;
- each R 22 is independently H, F, Cl, or straight chained or branched C 1 -C 4 alkyl
- the invention provides a method of treating a subject suffering from anxiety which comprises administering to the subject an amount of compound effective to treat the subject's anxiety wherein the compound has the structure:
- each of Y 1 , Y 2 , Y 3 , and Y 4 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 4 , —SR 4 , —OCOR 4 , —COR 4 , —NCOR 4 , —N(R 4 ) 2 , —CON(R 4 ) 2 , or —COOR 4 ; aryl or heteroaryl; or any two of Y 1 , Y 2 , Y 3 and Y 4 present on adjacent carbon atoms can
- each R 4 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl(C 1 -C 6 )alkyl;
- A is A′, straight chained or branched C 1 -C 7 alkyl, aryl, heteroaryl, aryl(C 1 -C 6 )alkyl or heteroaryl (C 1 -C 6 ) alkyl;
- R 1 and R 2 are each independently H, straight chained or branched C 1 -C 7 alkyl, —F, —Cl, —Br, —I, —NO 2 , or —CN;
- R 3 is H, straight chained or branched C 1 -C 7 alkyl, —F, —Cl, —Br, —I, —NO 2 , —CN, —OR 6 aryl or heteroaryl;
- R 5 is straight chained or branched C 1 -C 7 alkyl, —N(R 4 ) 2 , —OR 6 or aryl;
- R 6 is straight chained or branched C 1 -C 7 alkyl or aryl
- B is aryl, or heteroaryl; provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following —F, —Cl, —Br, —I, —CN, methyl, ethyl or methoxy;
- n is an integer from 1 to 4 inclusive
- the invention provides a method of treating a subject suffering from anxiety which comprises administering to the subject an amount of compound effective to treat the subject's anxiety wherein the compound has the structure:
- each of Y 1 , Y 2 , Y 3 , and Y 4 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 4 , —SR 4 , —OCOR 4 , —COR 4 , —NCOR 4 , —N(R 4 ) 2 , —CON(R 4 ) 2 , or —COOR 4 ; aryl or heteroaryl; or any two of Y 1 , Y 2 , Y 3 and Y 4 present on adjacent carbon atoms can
- each R 4 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl(C 1 -C 6 )alkyl;
- A is A′, straight chained or branched C 1 -C 7 alkyl, aryl, heteroaryl, aryl(C 1 -C 6 )alkyl or heteroaryl (C 1 -C 6 ) alkyl;
- B is aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, tricyclic heteroaryl or Q 6 ;
- a tricyclic heteroaryl is a fused three ring aromatic system in which one or more of the rings is heteroaryl; carbazole; or acridine;
- n is an integer from 1 to 4 inclusive
- each R 22 is independently H, F,
- the invention provides a method of treating a subject suffering from anxiety which comprises administering to the subject an amount of compound effective to treat the subject's anxiety wherein the compound has the structure:
- each of Y 1 , Y 2 , Y 3 , and Y 4 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 4 , —SR 4 , —OCOR 4 , —COR 4 , —NCOR 4 , —N(R 4 ) 2 , —CON(R 4 ) 2 , or —COOR 4 ; aryl or heteroaryl; or any two of Y 1 , Y 2 , Y 3 and Y 4 present on adjacent carbon atoms can
- each R 4 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl(C 1 -C 6 )alkyl;
- A is Q 3 , Q 4 , Q 5 , aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, or (CHR 17 )—(CHR 17 ) n —Z;
- each R 17 is independently H; straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) n —O—(CH 2 ) m —CH 3 ;
- each R 20 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , or —COOR 21 ; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 21 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl or aryl;
- each R 22 is independently H, F, Cl, or straight chained or branched C 1 -C 4 alkyl
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- each p is an integer from 0 to 2 inclusive;
- U is O, —NR 16 , S, C(R 17 ) 2 , or —NSO 2 R 16 ;
- Z is C 3 -C 10 cycloalkyl, C 4 -C 7 cyclic ether, C 4 -C 7 cyclic thioether, aryl, or heteroaryl;
- R 1 is straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- B is aryl, or heteroaryl; provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following —F, —Cl, —Br, —I, —CN, methyl, ethyl or methoxy;
- the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the structure:
- each of Y 1 , Y 2 , Y 3 , and Y 4 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 4 , —SR 4 , —OCOR 4 , —COR 4 , —NCOR 4 , N(R 4 ) 2 , —CON(R 4 ) 2 , or —COOR 4 ; aryl or heteroaryl; or any two of Y 1 , Y 2 , Y 3 and Y 4 present on adjacent carbon atoms can constitute
- each R 4 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl(C 1 -C 6 )alkyl;
- A is A′, Q 3 , Q 4 , Q 5 , straight chained or branched C 1 -C 7 alkyl, aryl, heteroaryl, aryl(C 1 -C 6 )alkyl, heteroaryl(C 1 -C 6 )alkyl, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl; or (CHR 17 )—(CHR 17 ) n —Z;
- R 1 and R 2 are each independently H, straight chained or branched C 1 -C 7 alkyl, —F, —Cl, —Br, —I, —NO 2 , or —CN;
- R 3 is H, straight chained or branched C 1 -C 7 alkyl, —F, —Cl, —Br, —I, —NO 2 , —CN, —OR 6 , aryl or heteroaryl;
- R 5 is straight chained or branched C 1 -C 7 alkyl, —N(R 4 ) 2 , —OR 6 or aryl;
- R 6 is straight chained or branched C 1 -C 7 alkyl or aryl
- each R 17 is independently H; straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) n —O—(CH 2 ) m —CH 3 ;
- each R 20 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , or —COOR 21 ; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 21 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl(C 1 -C 6 )alkyl;
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- each p is an integer from 0 to 2 inclusive;
- U is O, —NR 16 , S, C(R 17 ) 2 , or —NSO 2 R 16 ;
- Z is C 3 -C 10 cycloalkyl, C 4 -C 7 cyclic ether, C 4 -C 7 cyclic thioether, aryl, or heteroaryl;
- R 16 is straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- B is aryl, heteroaryl, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, tricyclic heteroaryl or Q 6 ; provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following —F, —Cl, —Br, —I, —CN, methyl, ethyl or methoxy;
- a tricyclic heteroaryl is a fused three member aromatic system in which one or more of the rings is heteroaryl; carbazole; or acridine;
- each R 22 is independently H, F, Cl, or straight chained or branched C 1 -C 4 alkyl
- the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the structure:
- each of Y 1 , Y 2 , Y 3 , and Y 4 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 4 , —SR 4 , —OCOR 4 , —COR 4 , —NCOR 4 , —N(R 4 ) 2 , —CON(R 4 ) 2 , or —COOR 4 ; aryl or heteroaryl; or any two of Y 1 , Y 2 , Y 3 and Y 4 present on adjacent carbon atoms can
- each R 4 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl (C 1 -C 6 ) alkyl;
- A is A′, straight chained or branched C 1 -C 7 alkyl, aryl, heteroaryl, aryl(C 1 -C 6 )alkyl or heteroaryl (C 1 -C 6 ) alkyl;
- R 1 and R 2 are each independently H, straight chained or branched C 1 -C 7 alkyl, —F, —Cl, —Br, —I, —NO 2 , or —CN;
- R 3 is H, straight chained or branched C 1 -C 7 alkyl, —F, —Cl, —Br, —I, —NO 2 , —CN, —OR 6 aryl or heteroaryl;
- R 5 is straight chained or branched C 1 -C 7 alkyl, —N(R 4 ) 2 , —OR 6 or aryl;
- R 6 is straight chained or branched C 1 -C 7 alkyl or aryl
- B is aryl, or heteroaryl; provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following —F, —Cl, —Br, —I, —CN, methyl, ethyl or methoxy;
- n is an integer from 1 to 4 inclusive
- the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the structure:
- each of Y 1 , Y 2 , Y 3 , and Y 4 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 4 , —SR 4 , —OCOR 4 , —COR 4 , —NCOR 4 , —N(R 4 ) 2 , —CON(R 4 ) 2 , or —COOR 4 ; aryl or heteroaryl; or any two of Y 1 , Y 2 , Y 3 and Y 4 present on adjacent carbon atoms can
- each R 4 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl(C 1 -C 6 )alkyl;
- A is A′, straight chained or branched C 1 -C 7 alkyl, aryl, heteroaryl, aryl(C 1 -C 6 )alkyl or heteroaryl (C 1 -C 6 ) alkyl;
- B is aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, tricyclic heteroaryl or Q 6 ;
- a tricyclic heteroaryl is a fused three ring aromatic system in which one or more of the rings is heteroaryl; carbazole; or acridine;
- n is an integer from 1 to 4 inclusive
- each R 22 is independently H, F,
- the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the structure:
- each of Y 1 , Y 2 , Y 3 , and Y 4 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 4 , —SR 4 , —OCOR 4 , —COR 4 , —NCOR 4 , —N(R 4 ) 2 , —CON(R 4 ) 2 , or —COOR 4 ; aryl or heteroaryl; or any two of Y 1 , Y 2 , Y 3 and Y 4 present on adjacent carbon atoms can
- each R 4 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl (C 1 -C 6 ) alkyl;
- A is Q 3 , Q 4 , Q 5 , aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, or (CHR 17 )—(CHR 17 ) n —Z;
- each R 17 is independently H; straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) n —O—(CH 2 ) m —CH 3 ;
- each R 20 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , or —COOR 21 ; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 21 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl or aryl;
- each R 22 is independently H, F, Cl, or straight chained or branched C 1 -C 4 alkyl
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- each p is an integer from 0 to 2 inclusive;
- U is O, —NR 16 , S, C(R 17 ) 2 , or —NSO 2 R 16 ;
- Z is C 3 -C 10 cycloalkyl, C 4 -C 7 cyclic ether, C 4 -C 7 cyclic thioether, aryl, or heteroaryl;
- R 16 is straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- B is aryl, or heteroaryl; provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following —F, —Cl, —Br, —I, —CN, methyl, ethyl or methoxy;
- the invention provides a compound having the structure:
- each of Y 1 , Y 2 , Y 3 , and Y 4 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 4 , —SR 4 , —OCOR 4 , —COR 4 , —NCOR 4 , —N(R 4 ) 2 , —CON(R 4 ) 2 ; or —COOR 4 ; aryl or heteroaryl; or any two of Y 1 , Y 2 , Y 3 and Y 4 present on adjacent carbon atoms can
- each R 4 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl (C 1 -C 6 ) alkyl;
- A is A′, Q 3 , Q 4 , Q 5 , straight chained or branched C 1 -C 7 alkyl, aryl, heteroaryl, aryl(C 1 -C 6 )alkyl, heteroaryl (C 1 -C 6 ) alkyl, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl; or (CHR 17 )—(CHR 17 ) n —Z;
- R 1 and R 2 are each independently H, straight chained or branched C 1 -C 7 alkyl, —F, —Cl, —Br, —I, —NO 2 , or —CN;
- R 3 is H, straight chained or branched C 1 -C 7 alkyl, —F, —Cl, —Br, —I, —NO 2 , —CN, —OR 6 , aryl or heteroaryl;
- R 5 is straight chained or branched C 1 -C 7 alkyl, —N(R 4 ) 2 , —OR 6 or aryl;
- R 6 is straight chained or branched C 1 -C 7 alkyl or aryl
- each R 17 is independently H; straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) n —O—(CH 2 ) m —CH 3 ;
- each R 20 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , or —COOR 21 ; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 21 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl(C 1 -C 6 )alkyl;
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- each p is an integer from 0 to 2 inclusive;
- U is O, —NR 16 , S, C(R 17 ) 2 , or —NSO 2 R 16 ;
- Z is C 3 -C 10 cycloalkyl, C 4 -C 7 cyclic ether, C 4 -C 7 cyclic thioether, aryl, or heteroaryl;
- R 16 is straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- B is aryl, heteroaryl, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, tricyclic heteroaryl or Q 6 ; provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following —F, —Cl, —Br, —I, —CN, methyl, ethyl or methoxy;
- a tricyclic heteroaryl is a fused three member aromatic system in which one or more of the rings is heteroaryl; carbazole; or acridine;
- each R 22 is independently, H, F, Cl, or straight chained or branched C 1 -C 4 alkyl;
- the invention provides a compound having the structure:
- each of Y 1 , Y 2 , Y 3 , and Y 4 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 4 , —SR 4 , —OCOR 4 , —COR 4 , —NCOR 4 , —N(R 4 ) 2 , —CON(R 4 ) 2 , or —COOR 4 ; aryl or heteroaryl; or any two of Y 1 , Y 2 , Y 3 and Y 4 present on adjacent carbon atoms can
- each R 4 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl(C 1 -C 6 )alkyl;
- A is A′, straight chained or branched C 1 -C 7 alkyl, aryl, heteroaryl, aryl(C 1 -C 6 )alkyl or heteroaryl (C 1 -C 6 )alkyl;
- R 1 and R 2 are each independently H, straight chained or branched C 1 -C 7 alkyl, —F, —Cl, —Br, —I, —NO 2 , or —CN;
- R 3 is H, straight chained or branched C 1 -C 7 alkyl, —F, —Cl, —Br, —I, —NO 2 , —CN, —OR 6 aryl or heteroaryl;
- R 5 is straight chained or branched C 1 -C 7 alkyl, —N(R 4 ) 2 , —OR 6 or aryl;
- R 6 is straight chained or branched C 1 -C 7 alkyl or aryl
- B is aryl, or heteroaryl; provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following —F, —Cl, —Br, —I, —CN, methyl, ethyl or methoxy;
- n is an integer from 1 to 4 inclusive
- the invention provides a compound having the structure:
- each of Y 1 , Y 2 , Y 3 , and Y 4 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 4 , —SR 4 , —OCOR 4 , —COR 4 , —NCOR 4 , —N(R 4 ) 2 , —CON(R 4 ) 2 , or —COOR 4 ; aryl or heteroaryl; —OR any two of Y 1 , Y 2 , Y 3 and Y 4 present on adjacent carbon atom
- each R 4 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl(C 1 -C 6 )alkyl;
- A is A′, straight chained or branched C 1 -C 7 alkyl, aryl, heteroaryl, aryl(C 1 -C 6 )alkyl or heteroaryl(C 1 -C 6 )alkyl;
- B is aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, tricyclic heteroaryl or Q 6 ;
- a tricyclic heteroaryl is a fused three ring aromatic system in which one or more of the rings is heteroaryl; carbazole; or acridine;
- n is an integer from 1 to 4 inclusive
- each R 22 is independently H, F, Cl, or straight chained or branched C 1 -C 4 alkyl
- the invention provides a compound having the structure:
- each of Y 1 , Y 2 , Y 3 , and Y 4 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 4 , —SR 4 , —OCOR 4 , —COR 4 , —NCOR 4 , —N(R 4 ) 2 , —CON(R 4 ) 2 , or —COOR 4 ; aryl or heteroaryl; or any two of Y 1 , Y 2 , Y 3 and Y 4 present on adjacent carbon atoms can
- each R 4 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl(C 1 -C 6 )alkyl;
- A is Q 3 , Q 4 , Q 5 , aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, or (CHR 17 )—(CHR 17 ) n —Z;
- each R 17 is independently —H; straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) n —O—(CH 2 ) m —CH 3 ;
- each R 20 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , or —COOR 21 ; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 21 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl or aryl;
- each R 22 is independently H, F, Cl, or straight chained or branched C 1 -C 4 alkyl
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- each p is an integer from 0 to 2 inclusive;
- U is O, —NR 16 , S, C(R 17 ) 2 , or —NSO 2 R 16 ;
- Z is C 3 -C 10 cycloalkyl, C 4 -C 7 , cyclic ether, C 4 -C 7 cyclic thioether, aryl, or heteroaryl;
- R 16 is straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- B is aryl, or heteroaryl; provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following —F, —Cl, —Br, —I, —CN, methyl, ethyl or methoxy;
- the invention provides a method of treating depression in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GAL3 receptor antagonist, wherein:
- the GAL3Receptor antagonist binds to the human GAL3 Receptor with a binding affinity at least ten-Fold higher than the binding affinity with which it binds to the human GAL1 receptor;
- the GAL3Receptor antagonist does not inhibit the activity of central monoamine oxidase B greater than 50 percent, at a concentration of 10 ⁇ M;
- the GAL3Receptor antagonist binds to the human GAL3Receptor with a binding affinity at least ten-fold higher than the binding affinity with which it binds to each of the following transporters: serotonin transporter, norepinephrine transporter, and dopamine transporter.
- the invention provides a method of treating anxiety in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GAL3 receptor antagonist, wherein:
- the GAL3Receptor antagonist binds to the human GAL3 receptor with a binding affinity at least ten-Fold higher than the binding affinity with which it binds to the human GAL1 receptor;
- the GAL3Receptor antagonist binds to the human GAL3 receptor with a binding affinity at least ten-Fold higher than the binding affinity with which it binds to each of the following transporters: serotonin transporter, norepinephrine transporter, and dopamine transporter.
- FIG. 1 Rat Forced Swim Test Results (Immobility: Normal Rats)
- FIG. 2 Rat Forced Swim Test Results (Climbing: Normal Rats)
- Example 92 A significant increase in climbing was observed for rats injected with Example 92 at 10 mg/kg, relative to vehicle injected controls (p ⁇ 0.01, ANOVA and Student-Nerman-Keuls), but not in rats dosed with Example 92 at 30 mg/kg ip.
- FIG. 3 Rat Forced Swim Test Results (Swimming: Normal Rats)
- FIG. 4 Social Interaction Test Results (Social Interaction: Unfamiliar Rats)
- Example 92 When the dose of Example 92 was increased to 100 mg/kg, the amount of social interaction time was significantly less than measured after chlordiazepoxide at 5 mg/kg ip or Example 92 at 30 mg/kg ip (p ⁇ 0.01). Significance in all cases was determined by ANOVA and Student-Nerman-Keuls.
- FIG. 5 Western Blot Results
- the anti-GAL3 antiserum labeled proteins in membranes only from rat GAL3-transfected cells (Lane 2); a predominant band was evident with an apparent molecular weight of approximately 56 kDa, (somewhat higher than the amino acid-derived value of 40.4 kDa).
- the apparently high molecular weight observed for rat GAL3 very likely reflects post-translational processing such as glycosylation; note that rat GAL3 contains multiple N-terminal glycosylation sites (Smith et al., 1998).
- Relative to the predominant band additional species of higher molecular weight as well as lower molecular weight were labeled by the GAL3 antiserum. These are interpreted as protein aggregates of C-terminal fragments, as they are absent in mock-transfected cells.
- the present invention provides a method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat the subject's depression wherein the compound has the structure:
- W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R 11 is H, straight chained or branched C 1 -C 7 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , aryl, or aryl (C 1 -C 6 )alkyl;
- R 12 is straight chained or branched C 1 -C 7 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 or —(CH 2 ) m —Z;
- R 13 is a bicyclic alkyl ring system, adamantyl, noradamantyl, C 3 -C 10 cycloalkyl, heteroaryl, aryl, aryl(C 1 -C 6 ) alkyl, Q 1 or Q 2 ;
- aryl may be substituted with one or more C 1 -C 10 straight chained or branched alkyl, aryl, heteroaryl, or N(R 19 )—z;
- each J is independently O, S, C(R 22 ) 2 or NR 4 ;
- R 4 is H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl or aryl;
- R 14 is H, straight chained or branched C 1 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m —Z;
- R 15 is straight chained or branched C 3 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, (C(R 19 ) 2 ) m N(R 16 ) 2 or (C(R 19 ) 2 ) m —Z ;
- R 16 is straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 17 is independently H; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , —COOR 21 , straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) n —O—(CH 2 ) m —CH 3 ;
- R 18 is straight chained or branched C 1 -C 6 alkyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 19 is independently H, or straight chained or branched C 1 -C 6 alkyl
- each R 20 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , or —COOR 21 ; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 21 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl, or aryl(C 1 -C 6 ) alkyl;
- each R 22 is independently H, F, Cl or C 1 -C 4 straight chained or branched alkyl
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- U is O, —NR 16 , S, C(R 17 ) 2 , or —NSO 2 R 16 ;
- Z is C 3 -C 10 cycloalkyl, C 4 -C 7 cyclic ether, C 4 -C 7 cyclic thioether, aryl, or heteroaryl; or
- the invention provides a method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat the subject's depression wherein the compound has the structure:
- W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R 11 is H, straight chained or branched C 1 -C 7 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , aryl or aryl(C 1 -C 6 ) alkyl;
- R 12 is straight chained or branched C 1 -C 7 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , or —(CH 2 ) m —Z;
- R 13 is a bicyclic alkyl ring system, aryl or aryl (C 1 -C 6 )alkyl;
- R 14 is H, straight chained or branched C 1 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m —Z;
- R 15 is straight chained or branched C 3 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m —Z;
- U is O, —NR 16 , S, C(R 17 ) 2 , or —NSO 2 R 16 ;
- Z is C 3 -C 10 cycloalkyl, aryl, or heteroaryl
- R 16 is straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 17 is independently H; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , —COOR 21 , straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) n —O—(CH 2 ) m —CH 3 ;
- R 18 is straight chained or branched C 1 -C 6 alkyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 19 is independently H, or straight chained or branched C 1 -C 6 alkyl
- each R 20 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , or —COOR 21 ; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 21 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl(C 1 -C 6 )alkyl;
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- the invention provides a method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat the subject's depression wherein the compound has the structure:
- W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R 13 is an aryl, adamantyl, noradamantyl, C 3 -C 10 cycloalkyl, heteroaryl, Q 1 or Q 2 ;
- aryl may be substituted with one or more C 1 -C 10 straight chained or branched alkyl, aryl, heteroaryl, or N(R 19 )—Z;
- each J is independently O, S, C(R 22 ) 2 or NR 4 ;
- R 4 is —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl or aryl;
- R 14 is H, straight chained or branched C 1 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m —Z;
- R 15 is straight chained or branched C 3 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m —Z;
- U is O, —NR 16 , S, C(R 17 ) 2 , or —NSO 2 R 16 ;
- Z is C 3 -C 10 cycloalkyl, aryl, or heteroaryl
- R 16 is straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 17 is independently H; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , —COOR 21 , straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) n —O—(CH 2 ) m —CH 3 ;
- R 18 is straight chained or branched C 1 -C 6 alkyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 19 is independently H, or straight chained or branched C 1 -C 6 alkyl
- each R 20 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , or —COOR 21 ; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 21 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl(C 1 -C 6 )alkyl;
- each R 22 is independently H, F, Cl or C 1 -C 4 straight chained or branched alkyl
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- the invention provides a method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat the subject's depression wherein the compound has the structure:
- W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R 13 is a bicyclic alkyl ring system, aryl or aryl (C 1 -C 6 )alkyl;
- R 14 is H, straight chained or branched C 1 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m —Z;
- R 15 is (C(R 19 ) 2 ) m —N(R 16 ) 2 ;
- Z is C 3 -C 10 cycloalkyl, aryl, or heteroaryl
- R 16 is straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 17 is independently H; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , —COOR 21 , straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) n —O—(CH 2 ) m —CH 3 ;
- each R 19 is independently H, or straight chained or branched C 1 -C 6 alkyl
- each R 21 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl(C 1 -C 6 )alkyl;
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- bicyclic alkyl ring systems includes, but is not limited to, bicyclo[2.2.1]heptane, bicyclo[3.1.1]heptane and bicyclo[2.2.2]octane.
- the bicyclic alkyl ring systems may be substituted with one or more of the following: —F, —NO 2 , —CN, straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, —N(R 21 ) 2 , —OR 21 , —COR 21 , —CO 21 R 21 , —CON(R 21 ) 2 or (CH 2 ) n —O—(CH 2 ) m —CH 3 .
- cycloalkyl includes, C 3 -C 7 cycloalkyl moieties which may be substituted with one or more of the following: —F, —NO 2 , —CN, straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 3 -C 7 cycloalkyl, C 3 -C 7 monofluorocycloalkyl, C 3 -C 7 polyfluorocycloalkyl, C 5 -C 7 cycloalkenyl, —N(R 4 ) 2 , —OR 4 , —COR 4 , —NCOR 4 ,
- cyclohexyl includes, cyclohexyl groups which may be substituted with one or more of the following: —F, —NO 2 , —CN, straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 3 -C 7 cycloalkyl, C 3 -C 7 monofluorocycloalkyl, C 3 -C 7 polyfluorocycloalkyl, C 5 -C 7 cycloalkenyl, —N(R 4 ) 2 , —OR 4 , —COR 4 , —NCOR 4 , —CO 2 R 4
- cycloalkyl includes, C 5 -C 7 cycloalkenyl moieties which may be substituted with one or more of the following: —F, —Cl, —Br, —I, —NO 2 , —CN, straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 3 -C 7 cycloalkyl, C 3 -C 7 monofluorocycloalkyl, C 3 -C 7 polyfluorocycloalkyl, C 5 -C 7 cycloalkenyl, —N(R 4 ) 2 , —OR 4
- heteroaryl is used to include five and six membered unsaturated rings that may contain one or more oxygen, sulfur, or nitrogen atoms.
- heteroaryl groups include, but are not limited to, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl.
- heteroaryl is used to include fused bicyclic ring systems that may contain one or more heteroatoms such as oxygen, sulfur and nitrogen.
- heteroaryl groups include, but are not limited to, indolizinyl, indolyl, isoindolyl, benzo[b]furanyl, benzo[b]thiophenyl, indazolyl, benzimidazolyl, purinyl, benzoxazolyl, benzisoxazolyl, benzo[b]thiazolyl, imidazo[2,1-b]thiazolyl, cinnolinyl, quinazolinyl, quinoxalinyl, 1,8-Naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, phthalimidyl and 2,1,3-benzothiazolyl.
- heteroaryl also includes those chemical moieties recited above which may be substituted with one or more of the following: —F, —Cl, —Br, —I, —NO 2 , —CN, straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 3 -C 7 cycloalkyl, C 3 -C 7 monofluorocycloalkyl, C 3 -C 7 polyfluorocycloalkyl, C 5 -C 7 cycloalkenyl, —N(R 4 ) 2 , —OR 4 , —COR 4 , —NCOR 4
- heteroaryl further includes the N-oxides of those chemical moieties recited above which include at least one nitrogen atom.
- aryl is phenyl or naphthyl.
- the term “aryl” also includes phenyl and naphthyl which may be substituted with one or more of the following: —F, —Cl, —Br, —I, —NO 2 , —CN, straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 3 -C 7 cycloalkyl, C 3 -C 7 monofluorocycloalkyl, C 3 -C 7 polyfluorocycloalkyl, C 5 -C 7 cycloalkenyl, —N(R 4 ) 2
- the compound is enantiomerically and diasteriomerically pure. In one embodiment, the compound is enantiomerically or diasteriomerically pure.
- the compound in one embodiment of any of the methods described herein, can be administered orally.
- X is:
- X is NR 11 R 12 and R 11 is H or straight chained or branched C 1 -C 7 alkyl.
- the compound has the structure:
- R 13 is a bicyclic alkyl ring system, cyclohexyl or aryl.
- R 14 is H, straight chained or branched C 1 -C 6 alkyl or (CH 2 ) q —O—(CH 2 ) m —CH 3 .
- R 14 is H, straight chained or branched C 1 -C 6 alkyl or (CH 2 ) q —O—(CH 2 ) m —CH 3 .
- the compound is selected from the group consisting of:
- Y is
- U is NR 16 .
- R 16 is (CH 2 ) m —Z.
- Z is aryl or heteroaryl.
- the compound is selected from the group consisting of:
- the compound is selected from the group consisting of:
- Y is
- U is NR 16 .
- the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- the compound is selected from the group consisting of:
- the compound is selected from the group consisting of:
- X is N(CH 3 ) 2 .
- Y is
- R 13 is an aryl substituted with a C 1 -C 10 straight chained alkyl.
- the compound is selected from a group consisting of:
- the invention provides a method of treating a subject suffering from anxiety which comprises administering to the subject an amount of compound effective to treat the subject's anxiety wherein the compound has the structure:
- W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R 11 is H, straight chained or branched C 1 -C 7 alkyl, (CH 2 ) q —O—(CH 2 ) m CH 3 , aryl, or aryl (C 1 -C 6 )alkyl;
- R 12 is straight chained or branched C 1 -C 7 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , or —(CH 2 ) m —Z;
- R 13 is a bicyclic alkyl ring system, adamantyl, noradamantyl, C 3 -C 10 cycloalkyl, heteroaryl, aryl, aryl(C 1 -C 6 )alkyl, Q 1 or Q 2 ;
- aryl may be substituted with one or more C 1 -C 10 straight chained or branched alkyl, aryl, heteroaryl, or N(R 19 )—Z;
- each J is independently O, S, C(R 22 ) 2 or NR 4 ;
- R 4 is H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl or aryl;
- R 14 is H, straight chained or branched C 1 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m —Z;
- R 15 is straight chained or branched C 3 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, (C(R 19 ) 2 ) m N(R 16 ) 2 or (C(R 19 ) 2 ) m —Z;
- R 16 is straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 17 is independently H; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , —COOR 21 , straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) n —O—(CH 2 ) m —CH 3 ;
- R 18 is straight chained or branched C 1 -C 6 alkyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 19 is independently H, or straight chained or branched C 1 -C 6 alkyl
- each R 20 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , or —COOR 21 ; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 21 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl, or aryl(C 1 -C 6 )alkyl;
- each R 22 is independently H, F, Cl or C 1 -C 4 straight chained or branched alkyl
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- U is O, —NR 16 , S, C(R 17 ) 2 , or —NSO 2 R 16 ;
- Z is C 3 -C 10 cycloalkyl, C 4 -C 7 cyclic ether, C 4 -C 7 cyclic thioether, aryl, or heteroaryl; or
- the invention provides a method of treating a subject suffering from anxiety which comprises administering to the subject an amount of compound effective to treat the subject's anxiety wherein the compound has the structure:
- W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R 11 is H, straight chained or branched C 1 -C 7 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , aryl or aryl(C 1 -C 6 )alkyl;
- R 12 is straight chained or branched C 1 -C 7 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , or —(CH 2 ) m —Z;
- R 13 is a bicyclic alkyl ring system, aryl or aryl (C 1 -C 6 ) alkyl;
- R 14 is H, straight chained or branched C 1 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m —Z;
- R 15 is straight chained or branched C 3 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m —Z;
- U is O, —NR 16 , S, C(R 17 ) 2 , or —NSO 2 R 16 ;
- Z is C 3 -C 10 cycloalkyl, aryl, or heteroaryl
- R 16 is straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 17 is independently H; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , —COOR 21 , straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) n —O—(CH 2 ) m —CH 3 ;
- R 18 is straight chained or branched C 1 -C 6 alkyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 19 is independently H, or straight chained or branched C 1 -C 6 alkyl
- each R 20 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , or —COOR 21 ; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 21 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl(C 1 -C 6 )alkyl;
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- the invention provides a method of treating a subject suffering from anxiety which comprises administering to the subject an amount of compound effective to treat the subject's anxiety wherein the compound has the structure:
- W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R 13 is an aryl, adamantyl, noradamantyl, C 3 -C 10 cycloalkyl, heteroaryl, Q 1 or Q 2 ;
- aryl may be substituted with one or more C 1 -C 10 straight chained or branched alkyl, aryl, heteroaryl, or N(R 19 )—Z;
- each J is independently O, S, C(R 22 ) 2 or NR 4 ;
- R 4 is —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl or aryl;
- R 14 is H, straight chained or branched C 1 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m —Z;
- R 15 is straight chained or branched C 3 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m —Z;
- U is O, —NR 16 , S, C(R 17 ) 2 , or —NSO 2 R 16 ;
- Z is C 3 -C 10 cycloalkyl, aryl, or heteroaryl
- R 16 is straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 17 is independently H; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , —COOR 21 , straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) n —O—(CH 2 ) m —CH 3 ;
- R 18 is straight chained or branched C 1 -C 6 alkyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 19 is independently H, or straight chained or branched C 1 -C 6 alkyl
- each R 20 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , or —COOR 21 ; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 21 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl(C 1 -C 6 )alkyl;
- each R 22 is independently H, F, Cl or C 1 -C 4 straight chained or branched alkyl
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- the invention provides a method of treating a subject suffering from anxiety which comprises administering to the subject an amount of compound effective to treat the subject's anxiety wherein the compound has the structure:
- W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R 13 is a bicyclic alkyl ring system, aryl or aryl (C 1 -C 6 ) alkyl;
- R 14 is H, straight chained or branched C 1 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m —Z;
- R 15 is (C(R 19 ) 2 ) m —N(R 16 ) 2 ;
- Z is C 3 -C 10 cycloalkyl, aryl, or heteroaryl
- R 16 is straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 17 is independently H; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , —COOR 21 , straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) n —O—(CH 2 ) m —CH 3 ;
- each R 19 is independently H, or straight chained or branched C 1 -C 6 alkyl
- each R 21 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl(C 1 -C 6 )alkyl;
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- bicyclic alkyl ring systems includes, but is not limited to, bicyclo[2.2.1]heptane, bicyclo[3.1.1]heptane and bicyclo[2.2.2]octane.
- the bicyclic alkyl ring systems may be substituted with one or more of the following: —F, —NO 2 , —CN, straight chained or branched C 1 -C 7 alkyl, straight chained.
- cycloalkyl includes, C 3 -C 7 cycloalkyl moieties which may be substituted with one or more of the following: —F, —NO 2 , —CN, straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 3 -C 7 cycloalkyl, C 3 -C 7 monofluorocycloalkyl, C 3 -C 7 polyfluorocycloalkyl, C 5 -C 7 cycloalkenyl, —N(R 4 ) 2 , —OR 4 , —COR 4 , —NCOR 4 ,
- cyclohexyl includes, cyclohexyl groups which may be substituted with one or more of the following: —F, —NO 2 , —CN, straight chained or branched C 1 -C 7 alkyl, straight chained.
- C 1 -C 7 monofluoroalkyl straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 3 -C 7 cycloalkyl, C 3 -C 7 monofluorocycloalkyl, C 3 -C 7 polyfluorocycloalkyl, C 5 -C 7 cycloalkenyl, —N(R 4 ) 2 , —OR 4 , —COR 4 , —NCOR 4 , —CO 2 R 4 , —CON(R 4 ) 2 or (CH 2 ) n —O—(CH 2 ) m —CH 3 .
- cycloalkenyl includes, C 5 -C 7 cycloalkenyl moieties which may be substituted with one or more of the following: —F, —Cl, —Br, —I, —NO 2 , —CN, straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 3 -C 7 cycloalkyl, C 3 -C 7 monofluorocycloalkyl, C 3 -C 7 polyfluorocycloalkyl, C 5 -C 7 cycloalkenyl, —N(R 4 ) 2 , —OR 4
- heteroaryl is used to include five and six membered unsaturated rings that may contain one or more oxygen, sulfur, or nitrogen atoms.
- heteroaryl groups include, but are not limited to, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl.
- heteroaryl is used to include fused bicyclic ring systems that may contain one or more heteroatoms such as oxygen, sulfur and nitrogen.
- heteroaryl groups include, but are not limited to, indolizinyl, indolyl, isoindolyl, benzo[b]furanyl, benzo[b]thiophenyl, indazolyl, benzimidazolyl, purinyl, benzoxazolyl, benzisoxazolyl, benzo[b]thiazolyl, imidazo[2,1-b]thiazolyl, cinnolinyl, quinazolinyl, quinoxalinyl, 1,8-Naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, phthalimidyl and 2,1,3-benzothiazolyl.
- heteroaryl also includes those chemical moieties recited above which may be substituted with one or more of the following: —F, —Cl, —Br, —I, —NO 2 , —CN, straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 3 -C 7 cycloalkyl, C 3 -C 7 monofluorocycloalkyl, C 3 -C 7 polyfluorocycloalkyl, C 5 -C 7 cycloalkenyl, —N(R 4 ) 2 , —OR 4 , —COR 4 , —NCOR 4 , —CO
- heteroaryl further includes the N-oxides of those chemical moieties recited above which include at least one nitrogen atom.
- aryl is phenyl or naphthyl.
- the term “aryl” also includes phenyl and naphthyl which may be substituted with one or more of the following: —F, —Cl, —Br, —I, —NO 2 , —CN, straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 3 -C 7 cycloalkyl, C 3 -C 7 monofluorocycloalkyl, C 3 -C 7 polyfluorocycloalkyl, C 5 -C 7 cycloalkenyl, —N(R 4 ) 2
- the compound is enantiomerically and diasteriomerically pure. In one embodiment, the compound is enantiomerically or diasteriomerically pure.
- the compound can be administered orally.
- X is:
- X is NR 11 R 12 and R 11 is H or straight chained or branched C 1 -C 7 alkyl.
- the compound has the structure:
- R 13 is a bicyclic alkyl ring system, cyclohexyl or aryl.
- R 14 is H, straight chained or branched C 1 -C 6 alkyl or (CH 2 ) q —O—(CH 2 ) m —CH 3 .
- the compound is selected from the group consisting of:
- Y is
- U is NR 16 .
- R 16 is (CH 2 ) m —Z.
- Z is aryl or heteroaryl.
- the compound is selected from the group consisting of:
- the compound is selected from the group consisting of:
- Y is
- U is NR 16 .
- the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- the compound is selected from the group consisting of:
- the compound is selected from the group consisting of:
- X is N(CH 3 ) 2 .
- Y is
- R 13 is an aryl substituted with a C 1 -C 10 straight chained alkyl.
- the compound is selected from a group consisting of:
- the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the structure:
- W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R 11 is H, straight chained or branched C 1 -C 7 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , aryl, or aryl (C 1 -C 6 )alkyl;
- R 12 is straight chained or branched C 1 -C 7 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , or —(CH 2 ) m —Z;
- R 13 is a bicyclic alkyl ring system, adamantyl, noradamantyl, C 3 -C 10 cycloalkyl, heteroaryl, aryl, aryl(C 1 -C 6 )alkyl, Q 1 or Q 2 ;
- aryl may be substituted with one or more C 1 -C 10 straight chained or branched alkyl, aryl, heteroaryl, or N(R 19 )—Z;
- each J is independently O, S, C(R 22 ) 2 or NR 4 ;
- R 4 is H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl or aryl;
- R 14 is H, straight chained or branched C 1 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m —Z;
- R 15 is straight chained or branched C 3 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, (C(R 19 ) 2 ) m N(R 16 ) 2 or (C(R 19 ) 2 ) m —Z;
- R 16 is straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, (CH 2 ) m ⁇ Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 17 is independently H; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , —COOR 21 , straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) n —O—(CH 2 ) m —CH 3 ;
- R 18 is straight chained or branched C 1 -C 6 alkyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 19 is independently H, or straight chained or branched C 1 -C 6 alkyl
- each R 20 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , or —COOR 21 ; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 21 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl, or aryl(C 3 -C 6 )alkyl;
- each R 22 is independently H, F, Cl or C 1 -C 4 straight chained or branched alkyl
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- U is O, —NR 16 , S, C(R 17 ) 2 , or —NSO 2 R 16 ;
- Z is C 3 -C 10 cycloalkyl, C 4 -C 7 cyclic ether, C 4 -C 7 cyclic thioether, aryl, or heteroaryl; or
- the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the structure:
- W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R 11 is H, straight chained or branched C 1 -C 7 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , aryl or aryl(C 1 -C 6 )alkyl;
- R 12 is straight chained or branched C 1 -C 7 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , or —(CH 2 ) m —Z;
- R 13 is a bicyclic alkyl ring system, aryl or aryl (C 1 -C 6 ) alkyl;
- R 14 is H, straight chained or branched C 1 -C 6 alkyl, (CH 2 ) q —O—(CH 2 ) m —CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m —Z ;
- R 15 is straight chained or branched C 3 -C 6 alkyl, (CH 2 ) q —O—(CH 2 )_—CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m —Z;
- U is O, —NR 16 , S, C(R 17 ) 2 , or —NSO 2 R 16 ;
- Z is C 3 -C 10 cycloalkyl, aryl, or heteroaryl
- R 16 is straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 17 is independently H; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 , —COOR 21 , straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, —(CH 2 ) m —Z, or (CH 2 ) n —O—(CH 2 ) m —CH 3 ;
- R 18 is straight chained or branched C 1 -C 6 alkyl, —(CH 2 ) m —Z, or (CH 2 ) q —O—(CH 2 ) m —CH 3 ;
- each R 19 is independently H, or straight chained or branched C 1 -C 6 alkyl
- each R 20 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; —F, —Cl, —Br, or —I; —NO 2 ; —N 3 ; —CN; —OR 21 , —OCOR 21 , —COR 21 , —NCOR 21 , —N(R 21 ) 2 , —CON(R 21 ) 2 or —COOR 21 ; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 21 is independently —H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl(C 1 -C 6 )alkyl;
- each m is an integer from 0 to 4 inclusive;
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/723,961 US20040127502A1 (en) | 2001-01-31 | 2003-11-26 | Use of GAL3 antagonist for treatment of depression |
US11/517,589 US7465750B2 (en) | 2001-01-31 | 2006-09-06 | Use of GAL3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods |
US12/314,675 US20090318504A1 (en) | 2001-01-31 | 2008-12-15 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26558601P | 2001-01-31 | 2001-01-31 | |
US10/066,175 US20030078271A1 (en) | 2001-01-31 | 2002-01-31 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods |
US10/723,961 US20040127502A1 (en) | 2001-01-31 | 2003-11-26 | Use of GAL3 antagonist for treatment of depression |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/066,175 Continuation US20030078271A1 (en) | 2001-01-31 | 2002-01-31 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/517,589 Continuation US7465750B2 (en) | 2001-01-31 | 2006-09-06 | Use of GAL3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040127502A1 true US20040127502A1 (en) | 2004-07-01 |
Family
ID=32658730
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/723,961 Abandoned US20040127502A1 (en) | 2001-01-31 | 2003-11-26 | Use of GAL3 antagonist for treatment of depression |
US11/517,589 Expired - Fee Related US7465750B2 (en) | 2001-01-31 | 2006-09-06 | Use of GAL3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods |
US12/314,675 Abandoned US20090318504A1 (en) | 2001-01-31 | 2008-12-15 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/517,589 Expired - Fee Related US7465750B2 (en) | 2001-01-31 | 2006-09-06 | Use of GAL3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods |
US12/314,675 Abandoned US20090318504A1 (en) | 2001-01-31 | 2008-12-15 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods |
Country Status (1)
Country | Link |
---|---|
US (3) | US20040127502A1 (US07465750-20081216-C00385.png) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030178369A1 (en) * | 2000-08-10 | 2003-09-25 | Tamiyuki Eguchi | Immersion type membrane filter |
US20040082587A1 (en) * | 2002-08-07 | 2004-04-29 | Mathivanan Packiarajan | 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety |
US20040092570A1 (en) * | 2002-08-07 | 2004-05-13 | Blackburn Thomas P. | GAL3 antagonists for the treatment of neuropathic pain |
US20040110821A1 (en) * | 2002-08-07 | 2004-06-10 | Konkel Michael J. | GAL3 receptor antagonists for the treatment of affective disorders |
US20050148635A1 (en) * | 2002-08-07 | 2005-07-07 | Michael Konkel | 3-imino-2-indolones for the treatment of depression and/or anxiety |
US7081470B2 (en) | 2001-01-31 | 2006-07-25 | H. Lundbeck A/S | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods |
US20060172989A1 (en) * | 2005-02-02 | 2006-08-03 | Michael Konkel | Aminoalkoxyphenyl indolone derivatives |
WO2007118899A1 (en) * | 2006-04-19 | 2007-10-25 | Abbott Gmbh & Co. Kg | Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5ht6 receptor |
EP1956006A1 (en) * | 2007-02-06 | 2008-08-13 | Laboratorios del Dr. Esteve S.A. | Heterocyclyl-substituted-tetrahydro-naphthalen derivatives as 5-HT7 receptor ligands |
EP1975161A1 (en) * | 2007-03-28 | 2008-10-01 | Laboratorios del Dr. Esteve S.A. | Heterocyclyl-substituted- tetrahydro-napthalen-amine derivatives, their preparation and use as medicaments |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040127502A1 (en) * | 2001-01-31 | 2004-07-01 | Synaptic Pharmaceutical Corporation | Use of GAL3 antagonist for treatment of depression |
US7642281B2 (en) * | 2002-08-07 | 2010-01-05 | Helicon Therapeutics, Inc. | Indolone compounds useful to treat cognitive impairment |
US20070135509A1 (en) * | 2005-12-09 | 2007-06-14 | Blackburn Thomas P | Indolone compounds useful to treat cognitive impairment |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4874687A (en) * | 1986-11-18 | 1989-10-17 | Fuji Photo Film Co., Ltd. | Method for forming an image |
US4921503A (en) * | 1988-09-12 | 1990-05-01 | Clairol Incorporated | Novel dyeing system |
US4946956A (en) * | 1988-09-21 | 1990-08-07 | Uniroyal Chemical Company, Inc. | Arylenediamine substituted pyrimidines |
US5017466A (en) * | 1989-05-24 | 1991-05-21 | Fuji Photo Film Co., Ltd. | Color-forming aminopyrimidine couplers and silver halide color photographic light-sensitive materials containing the coupler |
US5547949A (en) * | 1992-06-09 | 1996-08-20 | Richter Gedeon Vegyeszeti Gyar Rt. | Steroids with pregnane skeleton, pharmaceutical compositions containing them |
US5728704A (en) * | 1992-09-28 | 1998-03-17 | Pfizer Inc. | Substituted pyridmidines for control of diabetic complications |
US5801150A (en) * | 1993-06-23 | 1998-09-01 | Caillot; Jean-Luc | Aminopyri(mi)dine derivatives combined with amino acids, and pharmacological activities thereof |
US5840893A (en) * | 1995-01-06 | 1998-11-24 | The Picower Institute For Medical Research | Compounds for treating infectious diseases |
US5921503A (en) * | 1998-02-04 | 1999-07-13 | Tsay; Ing-Lang | Assistant landing device of a troubled airplane |
US6287788B1 (en) * | 1996-10-09 | 2001-09-11 | Synaptic Pharmaceutical Corporation | DNA encoding galanin GALR3 receptors and uses thereof |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1477349A (en) | 1975-09-24 | 1977-06-22 | Ciba Geigy Ag | Azo pigments |
US5198461A (en) | 1989-12-11 | 1993-03-30 | Neurosearch A/S | Isatine derivatives, their preparation and use |
JP3374136B2 (ja) | 1991-11-12 | 2003-02-04 | 三洋電機株式会社 | リチウム二次電池 |
HUT64323A (en) | 1992-06-09 | 1993-12-28 | Richter Gedeon Vegyeszet | Process for production new piperazinyl-bis(alkyl-amino)-pyrimidine derivatives |
ATE163647T1 (de) | 1993-08-26 | 1998-03-15 | Ono Pharmaceutical Co | 4-aminopyrimidin derivate |
US5565580A (en) | 1994-01-27 | 1996-10-15 | Neurosearch A/S | Glutamate Antagonists |
EP0788890A1 (en) | 1996-02-06 | 1997-08-13 | Agfa-Gevaert N.V. | Dyes and dye-donor elements for thermal dye transfer recording |
JP3319960B2 (ja) * | 1996-10-17 | 2002-09-03 | 富士通株式会社 | 半導体装置 |
JPH11158073A (ja) | 1997-09-26 | 1999-06-15 | Takeda Chem Ind Ltd | アデノシンa3拮抗剤 |
US6200977B1 (en) | 1998-02-17 | 2001-03-13 | Tularik Inc. | Pyrimidine derivatives |
EP0945442A1 (en) | 1998-03-27 | 1999-09-29 | Janssen Pharmaceutica N.V. | Trisubstituted pyrimidine derivatives |
SK287996B6 (sk) | 1998-03-27 | 2012-09-03 | Janssen Pharmaceutica N. V. | Pyrimide compound, pharmaceutical composition the compound is comprised, method for preparation thereof, combination and product containing the composition and use of the pyrimide compound |
WO1999065875A1 (en) | 1998-06-17 | 1999-12-23 | Geron Corporation | Telomerase inhibitors |
AU740813B2 (en) | 1998-07-08 | 2001-11-15 | Monash University | Pharmaceutical agents |
ATE205835T1 (de) | 1998-07-14 | 2001-10-15 | Basf Ag | Akarizid und insektizid wirksame, substituierte pyrimidine und verfahren zu ihrer herstellung |
US7081470B2 (en) * | 2001-01-31 | 2006-07-25 | H. Lundbeck A/S | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods |
US20040127502A1 (en) * | 2001-01-31 | 2004-07-01 | Synaptic Pharmaceutical Corporation | Use of GAL3 antagonist for treatment of depression |
US6996172B2 (en) | 2001-12-21 | 2006-02-07 | Motorola, Inc. | Method and structure for scalability type selection in digital video |
US20040082615A1 (en) * | 2002-08-07 | 2004-04-29 | Michael Konkel | 3-Imino-2-indolones for the treatement of depression and/or anxiety |
US7220775B2 (en) * | 2002-08-07 | 2007-05-22 | H. Lundbeck A/S | Compound useful for the treatment of neuropathic pain |
-
2003
- 2003-11-26 US US10/723,961 patent/US20040127502A1/en not_active Abandoned
-
2006
- 2006-09-06 US US11/517,589 patent/US7465750B2/en not_active Expired - Fee Related
-
2008
- 2008-12-15 US US12/314,675 patent/US20090318504A1/en not_active Abandoned
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4874687A (en) * | 1986-11-18 | 1989-10-17 | Fuji Photo Film Co., Ltd. | Method for forming an image |
US4921503A (en) * | 1988-09-12 | 1990-05-01 | Clairol Incorporated | Novel dyeing system |
US4946956A (en) * | 1988-09-21 | 1990-08-07 | Uniroyal Chemical Company, Inc. | Arylenediamine substituted pyrimidines |
US5017466A (en) * | 1989-05-24 | 1991-05-21 | Fuji Photo Film Co., Ltd. | Color-forming aminopyrimidine couplers and silver halide color photographic light-sensitive materials containing the coupler |
US5547949A (en) * | 1992-06-09 | 1996-08-20 | Richter Gedeon Vegyeszeti Gyar Rt. | Steroids with pregnane skeleton, pharmaceutical compositions containing them |
US5728704A (en) * | 1992-09-28 | 1998-03-17 | Pfizer Inc. | Substituted pyridmidines for control of diabetic complications |
US5801150A (en) * | 1993-06-23 | 1998-09-01 | Caillot; Jean-Luc | Aminopyri(mi)dine derivatives combined with amino acids, and pharmacological activities thereof |
US5840893A (en) * | 1995-01-06 | 1998-11-24 | The Picower Institute For Medical Research | Compounds for treating infectious diseases |
US6287788B1 (en) * | 1996-10-09 | 2001-09-11 | Synaptic Pharmaceutical Corporation | DNA encoding galanin GALR3 receptors and uses thereof |
US6329197B2 (en) * | 1996-10-09 | 2001-12-11 | Synaptic Pharmaceutical Corporation | DNA encoding galanin GALR3 receptors and uses thereof |
US6368812B1 (en) * | 1996-10-09 | 2002-04-09 | Synaptic Pharmaceutical Corporation | Process for determining the agonist or antagonist of galanin receptor (GALR3) |
US5921503A (en) * | 1998-02-04 | 1999-07-13 | Tsay; Ing-Lang | Assistant landing device of a troubled airplane |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030178369A1 (en) * | 2000-08-10 | 2003-09-25 | Tamiyuki Eguchi | Immersion type membrane filter |
US7868034B2 (en) | 2001-01-31 | 2011-01-11 | H. Lundbeck A/S | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods |
US20090176840A1 (en) * | 2001-01-31 | 2009-07-09 | Michael Konkel | Use of galr3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods |
US7081470B2 (en) | 2001-01-31 | 2006-07-25 | H. Lundbeck A/S | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods |
US6936607B2 (en) | 2002-08-07 | 2005-08-30 | H. Lunobeck A/S | 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety |
US20040092570A1 (en) * | 2002-08-07 | 2004-05-13 | Blackburn Thomas P. | GAL3 antagonists for the treatment of neuropathic pain |
US20040110821A1 (en) * | 2002-08-07 | 2004-06-10 | Konkel Michael J. | GAL3 receptor antagonists for the treatment of affective disorders |
US7166635B2 (en) | 2002-08-07 | 2007-01-23 | H. Lundbeck A/S | 3-imino-2-indolones for the treatment of depression and/or anxiety |
US20040082587A1 (en) * | 2002-08-07 | 2004-04-29 | Mathivanan Packiarajan | 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety |
US20050148635A1 (en) * | 2002-08-07 | 2005-07-07 | Michael Konkel | 3-imino-2-indolones for the treatment of depression and/or anxiety |
US20060172989A1 (en) * | 2005-02-02 | 2006-08-03 | Michael Konkel | Aminoalkoxyphenyl indolone derivatives |
WO2007118899A1 (en) * | 2006-04-19 | 2007-10-25 | Abbott Gmbh & Co. Kg | Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5ht6 receptor |
US8642642B2 (en) | 2006-04-19 | 2014-02-04 | Abbott Laboratories | Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor |
US20090306175A1 (en) * | 2006-04-19 | 2009-12-10 | Abbott Gmbh & Co. Kg | Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5ht6 receptor |
US20100035936A1 (en) * | 2007-02-06 | 2010-02-11 | Laboratorios Del Dr. Esteve, S.A. | Heterocyclyl substituted tetrahydronaphthalene derivatives as 5-ht7 receptor ligands |
WO2008095689A1 (en) * | 2007-02-06 | 2008-08-14 | Laboratorios Del Dr. Esteve, S.A. | Heterocyclyl substituted tetrahydronaphthalene derivatives as 5-ht7 receptor ligands |
US8097641B2 (en) | 2007-02-06 | 2012-01-17 | Laboratorios Del Dr. Esteve, S.A. | Heterocyclyl substituted tetrahydronaphthalene derivatives as 5-HT7 receptor ligands |
EP1956006A1 (en) * | 2007-02-06 | 2008-08-13 | Laboratorios del Dr. Esteve S.A. | Heterocyclyl-substituted-tetrahydro-naphthalen derivatives as 5-HT7 receptor ligands |
WO2008116663A3 (en) * | 2007-03-28 | 2008-11-06 | Esteve Labor Dr | Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments |
WO2008116663A2 (en) * | 2007-03-28 | 2008-10-02 | Laboratorios Del Dr. Esteve, S.A. | Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments |
EP1975161A1 (en) * | 2007-03-28 | 2008-10-01 | Laboratorios del Dr. Esteve S.A. | Heterocyclyl-substituted- tetrahydro-napthalen-amine derivatives, their preparation and use as medicaments |
US20100105684A1 (en) * | 2007-03-28 | 2010-04-29 | Laboratorios Del Dr. Esteve, S.A. | Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments |
US8236845B2 (en) | 2007-03-28 | 2012-08-07 | Laboratorios Del Dr. Esteve, S.A. | Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments |
Also Published As
Publication number | Publication date |
---|---|
US20070259942A1 (en) | 2007-11-08 |
US7465750B2 (en) | 2008-12-16 |
US20090318504A1 (en) | 2009-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7465750B2 (en) | Use of GAL3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods | |
US20030078271A1 (en) | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | |
US8198313B2 (en) | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | |
AU2008200385B2 (en) | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | |
US7220775B2 (en) | Compound useful for the treatment of neuropathic pain | |
US7166635B2 (en) | 3-imino-2-indolones for the treatment of depression and/or anxiety | |
AU2002247149A1 (en) | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | |
US20040110821A1 (en) | GAL3 receptor antagonists for the treatment of affective disorders | |
WO2004014307A2 (en) | Gal3 antagonists for the treatment of neuropathic pain | |
WO2004014376A1 (en) | Gal3 receptor antagonists for the treatment of affective disorders | |
US6936607B2 (en) | 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety | |
AU2008200380A1 (en) | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | |
WO2004034967A2 (en) | 2,4,6-triaminopyrimidines for the treatment of depression and/or anxiety |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: H. LUNDBECK A/S, DENMARK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SYNAPTIC PHARMACEUTICAL CORPORATION;REEL/FRAME:015156/0196 Effective date: 20031231 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE |